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background
 
Patients with nonischemic dilated cardiomyopathy are at substantial risk for sudden
death from cardiac causes. However, the value of prophylactic implantation of an im-
plantable cardioverter–defibrillator (ICD) to prevent sudden death in such patients is
unknown.
 
methods
 
We enrolled 458 patients with nonischemic dilated cardiomyopathy, a left ventricular
ejection fraction of less than 36 percent, and premature ventricular complexes or non-
sustained ventricular tachycardia. A total of 229 patients were randomly assigned to re-
ceive standard medical therapy, and 229 to receive standard medical therapy plus a sin-
gle-chamber ICD.
 
results
 
Patients were followed for a mean (±SD) of 29.0±14.4 months. The mean left ventric-
ular ejection fraction was 21 percent. The vast majority of patients were treated with an-
giotensin-converting–enzyme (ACE) inhibitors (86 percent) and beta-blockers (85
percent). There were 68 deaths: 28 in the ICD group, as compared with 40 in the stan-
dard-therapy group (hazard ratio, 0.65; 95 percent confidence interval, 0.40 to 1.06;
P=0.08). The mortality rate at two years was 14.1 percent in the standard-therapy group
(annual mortality rate, 7 percent) and 7.9 percent in the ICD group. There were 17 sud-
den deaths from arrhythmia: 3 in the ICD group, as compared with 14 in the standard-
therapy group (hazard ratio, 0.20; 95 percent confidence interval, 0.06 to 0.71; P=0.006).
 
conclusions
 
In patients with severe, nonischemic dilated cardiomyopathy who were treated with
ACE inhibitors and beta-blockers, the implantation of a cardioverter–defibrillator sig-
nificantly reduced the risk of sudden death from arrhythmia and was associated with a
nonsignificant reduction in the risk of death from any cause.
abstract
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atients with nonischemic dilated
 
cardiomyopathy often die suddenly.
 
1
 
 Al-
though therapy with angiotensin-convert-
ing–enzyme (ACE) inhibitors and beta-blockers has
increased survival in clinical trials of patients with
left ventricular dysfunction due to nonischemic and
ischemic cardiomyopathies, such patients still have
a substantial risk of sudden death from cardiac
causes despite receiving adequate doses of both
pharmacologic agents.
 
2,3
 
 The implantable cardio-
verter–defibrillator (ICD) prevents sudden death in
patients who have had an episode of ventricular
tachycardia or cardiac arrest,
 
4
 
 as well as in selected
patients who have coronary disease and left ventric-
ular dysfunction.
 
5-7
 
 However, no large-scale studies
have examined the role of the ICD in the primary
prevention of sudden death in patients with nonis-
chemic cardiomyopathy. Therefore, we tested the
hypothesis that an ICD will reduce the risk of death
in patients with nonischemic cardiomyopathy and
moderate-to-severe left ventricular dysfunction.
 
trial design
 
The Defibrillators in Non-Ischemic Cardiomyop-
athy Treatment Evaluation (DEFINITE) trial was a
prospective, randomized, investigator-initiated
study based on observational data
 
8
 
 and was funded
by St. Jude Medical, which did not have access to the
data. Data collection and analysis were indepen-
dently performed at Northwestern University under
the supervision of the statistical primary investiga-
tor. The investigators had full access to the data and
wrote the article.
Patients were randomly assigned to receive either
standard oral medical therapy for heart failure or
standard oral medical therapy plus an ICD. The pri-
mary end point of the study was death from any
cause. Sudden death from arrhythmia was a pre-
specified secondary end point.
 
9
 
The study was initially designed to have a statis-
tical power of 85 percent based on a one-sided test,
assuming two-year mortality rates of 15 percent in
the standard-therapy group and 7.5 percent in the
ICD group and the enrollment of 458 patients, with
56 deaths. In order to report results with the use of
two-sided tests and 85 percent statistical power, we
extended follow-up to include 68 deaths. Interim
analyses were performed after 22, 34, 45, 50, and
56 deaths. The critical values for the interim and fi-
nal analyses assumed an O’Brien–Fleming type of
spending function.
 
10-12
 
 For patients’ safety, bound-
aries for stopping the study in favor of the null hy-
pothesis of no effect of the ICD on the risk of death
at each interim analysis were also defined accord-
ing to the work of Whitehead and Stratton.
 
13
 
 No
boundaries were crossed at any of the five interim
analyses. Hence, this report presents the results of
the final analysis at the time of the 68th death. The
P value required for significance at the final analy-
p
methods
 
* ICD denotes implantable cardioverter–defibrillator, NYHA New York Heart As-
sociation, NSVT nonsustained ventricular tachycardia, PVCs premature ven-
tricular complexes, and LVEF left ventricular ejection fraction.
† Race and ethnic group were self-reported by the patients.
 
‡ P=0.04 for the comparison with the ICD group.
 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
All Patients 
(N=458)
Standard-
Therapy 
Group 
(N=229)
ICD Group 
(N=229)
 
Age — yr
Mean
Range
58.3
20.3–83.9
58.1
21.8–78.7
58.4
20.3–83.9
Male sex — no. (%) 326 (71.2) 160 (69.9) 166 (72.5)
Race or ethnic group — no. (%)†
White
Black
Hispanic
Pacific Islander
Asian
Other
308 (67.2)
118 (25.8)
26 (5.7)
1 (0.2)
1 (0.2)
4 (0.9)
154 (67.2)
59 (25.8)
13 (5.7)
0 
1 (0.4)
2 (0.9)
154 (67.2)
59 (25.8)
13 (5.7)
1 (0.4)
0 
2 (0.9)
History of diabetes — no. (%) 105 (22.9) 53 (23.1) 52 (22.7)
History of atrial fibrillation — no. (%) 112 (24.5) 60 (26.2) 52 (22.7)
Duration of heart failure — yr
Mean
Range
2.83
0.0–38.5
3.27‡
0.0–38.5
2.39
0.0–21.33
NYHA class — no. (%)
I
II
III
99 (21.6)
263 (57.4)
96 (21.0)
41 (17.9)
139 (60.7)
49 (21.4)
58 (25.3)
124 (54.2)
47 (20.5)
QRS interval — msec
Mean
Range
115.1
78–196
115.5
79–192
114.7
78–196
Bundle-branch block — no. (%)
Left
Right
90 (19.7)
15 (3.3)
45 (19.7)
7 (3.1)
45 (19.7)
8 (3.5)
Qualifying arrhythmia — no. (%)
NSVT only
PVCs only
NSVT and PVCs
103 (22.5)
43 (9.4)
312 (68.1)
52 (22.7)
22 (9.6)
155 (67.7)
51 (22.3)
21 (9.2)
157 (68.6)
LVEF — %
Mean
Range
21.4
7–35
21.8
10–35
20.9
7–35
Distance walked in 6 min — m
Mean
Range
319.4
18–1317
328.3
18–1317
311.2
29–1143
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sis was 0.041, on the basis of a two-sided test. The
first patient underwent randomization on July 9,
1998, and the 458th patient underwent randomiza-
tion on June 6, 2002. The 68th death occurred on
May 25, 2003.
The trial received annual approval from the in-
stitutional review board of Northwestern Universi-
ty as well as each of the study centers. Written in-
formed consent was obtained from all patients.
 
patient population
 
Inclusion criteria were a left ventricular ejection frac-
tion of less than 36 percent, the presence of ambi-
ent arrhythmias,
 
14
 
 a history of symptomatic heart
failure, and the presence of nonischemic dilated car-
diomyopathy. Ambient arrhythmias were defined by
an episode of nonsustained ventricular tachycardia
on Holter or telemetric monitoring (3 to 15 beats
at a rate of more than 120 beats per minute) or an
average of at least 10 premature ventricular com-
plexes per hour on 24-hour Holter monitoring. The
absence of clinically significant coronary artery dis-
ease as the cause of the cardiomyopathy was con-
firmed by coronary angiography or by a negative
stress imaging study. Patients were excluded if they
had New York Heart Association (NYHA) class IV
congestive heart failure, were not candidates for the
implantation of a cardioverter–defibrillator, had
undergone electrophysiological testing within the
prior three months, or had permanent pacemakers.
Patients in whom cardiac transplantation appeared
to be imminent, those with familial cardiomyopathy
associated with sudden death, and patients with
acute myocarditis or congenital heart disease were
also excluded.
 
pharmacologic therapy
 
All patients received ACE inhibitors unless they
were contraindicated. Patients who were unable to
tolerate ACE inhibitors received hydralazine or ni-
trates
 
15
 
 or angiotensin II–receptor blockers. In ad-
dition, beta-blocker therapy was required unless pa-
tients were unable to tolerate it. Carvedilol was the
beta-blocker of choice on the basis of data available
when the study was designed.
 
16
 
 The doses of ACE
inhibitors and beta-blockers were adjusted to the
levels recommended for patients with heart failure
or to the highest tolerated doses. Digoxin and di-
uretics were used when necessary to manage clini-
cal symptoms. The use of antiarrhythmic drugs such
as amiodarone was discouraged. However, it was
recognized that some patients had symptomatic
atrial fibrillation or supraventricular arrhythmias re-
quiring treatment with amiodarone, and these con-
ditions did not constitute exclusion criteria. No oth-
er antiarrhythmic drugs were used.
 
randomization and follow-up
 
Patients were randomly assigned to one of two
treatment groups, with 229 patients in each group.
Randomization was stratified according to center
and to the use or nonuse of amiodarone for su-
praventricular arrhythmias. Patients who were ran-
domly assigned to the ICD group received a single-
chamber device approved by the Food and Drug
Administration (St. Jude Medical). The ICDs were
programmed to back up VVI pacing at a rate of 40
beats per minute and to detect ventricular fibrilla-
tion at a rate of 180 beats per minute. All patients
were evaluated at three-month intervals. According
to prespecified criteria, patients who were random-
ly assigned to standard therapy received an ICD if
they had a cardiac arrest or an episode of unex-
plained syncope that was consistent with the occur-
rence of an arrhythmic event.
For patients who died, the cause of death was de-
termined by an events committee (see the Appendix)
whose members were unaware of patients’ treat-
ment assignments. The blinding process included
editing any information from progress notes or lab-
oratory reports that could have identified the pres-
ence of an ICD. The cause of death was determined
 
* ICD denotes implantable cardioverter–defibrillator, and ACE angiotensin-con-
 
verting enzyme.
 
Table 2. Pharmacologic Therapy.*
Agent
All Patients 
(N=458)
Standard-
Therapy 
Group
(N=229)
ICD Group
(N=229)
 
number of patients (percent)
 
ACE inhibitor 392 (85.6) 200 (87.3) 192 (83.8)
Beta-blocker
Carvedilol
Metoprolol
Other
389 (84.9)
263 (57.4)
102 (22.3)
24 (5.2)
193 (84.3)
134 (58.5)
43 (18.8)
16 (7.0)
196 (85.6)
129 (56.3)
59 (25.8)
8 (3.5)
Diuretic 397 (86.7) 197 (86.0) 200 (87.3)
Angiotensin II–receptor blocker 51 (11.1) 20 (8.7) 31 (13.5)
Amiodarone 24 (5.2) 15 (6.6) 9 (3.9)
Digoxin 192 (41.9) 97 (42.4) 95 (41.5)
Nitrate 51 (11.1) 30 (13.1) 21 (9.2)
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as suggested by Epstein et al.
 
17
 
 In this classification,
patients who had pump failure with progressive
symptomatic deterioration who died of terminal
ventricular fibrillation were not considered to have
had sudden death from arrhythmia.
 
statistical analysis
 
The baseline characteristics of the two groups were
compared with the use of two-sample t-tests for
continuous variables and chi-square tests for cate-
gorical variables. The log-rank test was used to
compare Kaplan–Meier survival curves in the two
groups, and the Cox proportional-hazards model
was used to adjust for covariates and to estimate the
hazard ratio for death and corresponding 95 percent
confidence interval in the ICD group as compared
with the standard-therapy group.
 
18
 
 All analyses
were conducted according to the intention to treat.
Data on patients who received a heart transplant
were censored at the time of transplantation, as
specified in the study protocol. The duration of fol-
low-up was computed from the time of randomiza-
tion to death for patients who died, and to the date
of the 68th death for patients who did not die. All
reported P values are two-tailed.
Follow-up lasted a mean (±SD) of 29.0±14.4
months. Baseline characteristics were similar in the
two groups, except for the duration of heart failure
(3.27 years in the standard-therapy group and 2.39
years in the ICD group, P=0.04) (Table 1).
 
therapy
 
The types of pharmacologic therapy used for heart
failure are shown in Table 2. The majority of pa-
tients were treated with beta-blockers and ACE in-
hibitors. Of the 229 patients in the ICD group, 227
received a functioning ICD system. Two patients de-
clined to undergo implantation of the ICD after pro-
viding consent and undergoing randomization. In
addition, in response to the patients’ requests, one
patient had the ICD explanted and one patient had
the device inactivated. All four patients were includ-
ed in the ICD group according to the intention to
treat.
There were three complications (1.3 percent)
during the implantation of the ICD: one hemotho-
rax, one pneumothorax, and one cardiac tampon-
ade. There were no procedure-related deaths, and
all complications resolved with medical therapy or
drainage. There were 10 complications during fol-
low-up (4.4 percent): 6 lead dislodgements or lead
fractures, 3 cases of venous thrombosis, and 1 in-
fection. Thirteen patients received ICD upgrades
during follow-up; 2 received dual-chamber ICDs
owing to the development of sinus-node dysfunc-
tion, and 11 received biventricular devices for NYHA
class III or IV heart failure and a prolonged QRS
interval. Of the 229 patients who were randomly
assigned to standard therapy, 23 (10.0 percent)
received ICDs during follow-up, primarily for syn-
cope or heart failure with a prolonged QRS interval.
results
 
Figure 1. Kaplan–Meier Estimates of Death from Any Cause (Panel A) and 
Sudden Death from Arrhythmia (Panel B) among Patients Who Received 
Standard Therapy and Those Who Received an Implantable Cardioverter–
Defibrillator (ICD).
 
In the ICD group, as compared with the standard-therapy group, the hazard 
ratio for death from any cause was 0.65 (95 percent confidence interval, 0.40 
to 1.06) and the hazard ratio for sudden death from arrhythmia was 0.20 
(95 percent confidence interval, 0.06 to 0.71).
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outcome
 
Fewer patients died in the ICD group than in the
standard-therapy group (28 vs. 40), but the differ-
ence in survival was not significant (P=0.08 by the
log-rank test) (Fig. 1). The unadjusted hazard ratio
for death among patients who received an ICD, as
compared with those who received standard thera-
py, was 0.65 (95 percent confidence interval, 0.40 to
1.06). The hazard ratio was unchanged (0.65) after
adjustment for the duration of heart failure. On the
basis of Kaplan–Meier survival curves, the rate of
death from any cause at one year was 6.2 percent in
the standard-therapy group and 2.6 percent in the
ICD group. At two years, it was 14.1 percent in the
standard-therapy group and 7.9 percent in the ICD
group.
An analysis according to treatment actually re-
ceived was also performed. The resulting hazard
ratio was 0.66 (95 percent confidence interval, 0.40
to 1.08).
There were 3 sudden deaths from arrhythmia in
the ICD group, as compared with 14 deaths in the
standard-therapy group (hazard ratio, 0.20; 95 per-
cent confidence interval, 0.06 to 0.71; P=0.006)
(Fig. 1). There were 11 deaths due to heart failure in
the standard-therapy group and 9 in the ICD group.
One death in the standard-therapy group was
thought to be from cardiac causes, but the events
committee could not distinguish between arrhyth-
mic and nonarrhythmic causes on the basis of the
available information. Of the 26 deaths that were
classified as noncardiac, 10 were due to cancer, 7 to
pneumonia, 5 to stroke, and 1 each to a drug over-
dose, suicide, liver failure, and renal failure. With re-
spect to the other four deaths (two in each group),
there was not enough information to determine the
cause of death. Some of these deaths could have
been due to arrhythmia.
During the follow-up period, 41 patients received
91 appropriate ICD shocks. In addition, 49 patients
 
Figure 2. Subgroup Analysis of the Relative Risk of Death from Any Cause among Patients Who Received an Implantable 
Cardioverter–Defibrillator (ICD), as Compared with Those Who Received Standard Therapy.
 
The dashed line indicates the hazard ratio for the overall population. None of the differences between subgroups were 
significant. LVEF denotes left ventricular ejection fraction, and NYHA New York Heart Association.
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received inappropriate ICD shocks, primarily for
atrial fibrillation or sinus tachycardia.
 
subgroup analysis
 
Although the study was not powered to detect dif-
ferences within subgroups, several prespecified
analyses were performed regarding variables that
could affect survival (Fig. 2). A Cox proportional-
hazards model was used to analyze differences in
survival in predefined subgroups. Men had a rela-
tive risk of death from any cause of 0.49 (95 percent
confidence interval, 0.27 to 0.90; P=0.018) after the
implantation of an ICD. Patients with NYHA class
III heart failure had a relative risk of death of 0.37
(95 percent confidence interval, 0.15 to 0.90; P=
0.02) after receiving an ICD (Fig. 3).
Our results indicate that patients with left ventricu-
lar dysfunction due to nonischemic cardiomyopathy
have an annual rate of death from any cause of about
7 percent when treated with standard medical ther-
apy for heart failure. Therapy with an ICD signifi-
cantly reduced the risk of sudden death from ar-
rhythmia (hazard ratio, 0.20; P=0.006) and resulted
in a reduction in the risk of death from any cause
that approached but did not reach statistical signif-
icance (hazard ratio, 0.65; P=0.08).
As in prior trials, the ICD was highly effective at
preventing sudden death from cardiac causes.
 
4-7
 
The difference in mortality between the standard-
therapy group and the ICD group was almost entire-
ly due to a difference in the incidence of death from
cardiac arrhythmia. On the basis of data available at
the time the study was designed, more than 50 per-
cent of the deaths were expected to be due to ar-
rhythmia, and thus, the trial was powered to detect
a 50 percent difference in the rates of death from any
cause. However, only approximately one third of the
deaths in the standard-therapy group were due to
arrhythmia. Eighty-five percent of the patients in
this study were treated with ACE inhibitors and beta-
blockers — a higher compliance rate than in other
studies.
 
4-7
 
 The lower-than-expected rate of sudden
death from arrhythmia may have been due to the
high rate of use of beta-blockers and ACE inhibi-
tors
 
19-23
 
 and may thus have resulted in the nonsig-
nificant reduction in deaths from any cause. Sub-
group analyses revealed that the implantation of an
ICD significantly reduced the risk of death among
patients who had NYHA class III heart failure and
among men. However, further studies will be re-
quired to determine whether these findings are clin-
ically important.
Prior large-scale studies evaluating the effect of
prophylactic implantation of an ICD for the preven-
tion of sudden death have focused on patients with
coronary disease.
 
5-7
 
 Our trial was designed to eval-
uate the effect of an ICD on the risk of death among
patients with nonischemic cardiomyopathy who
were receiving standard therapy, usually including
ACE inhibitors and beta-blockers. The second Mul-
ticenter Automatic Defibrillator Implantation Trial
(MADIT II) reported a decrease in the relative risk of
death from any cause of 31 percent among patients
who received an ICD — which was similar to our
finding of a 35 percent decrease.
 
7
 
Two recent small studies have examined the use
of ICDs in patients with nonischemic dilated cardio-
myopathy.
 
24,25
 
 Each of these studies randomly as-
signed only approximately 100 patients and failed
to show a benefit of the ICD. However, the sample
size of these studies was too small to show even a
moderate effect of the ICD on the risk of death.
 
24,25
 
Our study design did not include a group of pa-
tients who were treated with amiodarone. Several
discussion
 
Figure 3. Kaplan–Meier Survival Curves among Patients with New York Heart 
Association Class III Heart Failure, According to Whether They Received Stan-
dard Therapy or an Implantable Cardioverter–Defibrillator (ICD).
 
As compared with patients who received standard therapy, patients who re-
ceived an ICD had a relative risk of death from any cause of 0.37 (95 percent 
confidence interval, 0.15 to 0.90).
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previous studies have suggested that amiodarone
therapy slightly reduces the risk of death, especial-
ly in patients with nonischemic cardiomyopathy.
 
26
 
However, those data alone cannot be used to sup-
port the use of amiodarone as standard therapy in
this patient population.
 
25-27
 
 Since the data support-
ing the use of beta-blockers to improve survival were
clear at the time our study was designed, the use of
amiodarone was specifically discouraged owing to
concern that its use would limit the ability to titrate
beta-blockers to therapeutic doses. Aldosterone an-
tagonists were not used as standard therapy in this
study, since no survival benefit of these agents had
been demonstrated in patients with NYHA class I,
II, or III heart failure due to nonischemic cardiomy-
opathy.
 
28,29
 
On the basis of our results, the routine implanta-
tion of a cardioverter–defibrillator cannot be recom-
mended for all patients with nonischemic cardio-
myopathy and severe left ventricular dysfunction.
However, our findings of a reduction in sudden
death from arrhythmia and an apparent benefit of
ICDs in subgroup analyses suggest that the use of
these devices should be considered on a case-by-
case basis.
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